Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

CURRENT TRIALS

The Oxford Safer Pregnancy Alliance (OSPREA) is a team of doctors, scientists, researchers, midwives, nurses and support staff who work together with women to lead research into women’s health in the areas of reproduction, obstetrics and gynaecology. We conduct high quality studies that help improve the care of women before pregnancy, and women and their babies during and after pregnancy. 

We are primarily supported by the Nuffield Department of Women's & Reproductive Health, (part of the University of Oxford) the Oxford University Hospitals NHS Foundation Trust, and the Thames Valley & South Midlands Clinical Research Network, part of the National Institute for Health Research.

You can read about our current trials on this page below or find out more about OSPREA by clicking here. 

 

PREGNANCY STUDIES

Insight

 

 

 

 

The INSIGHT Study – Investigating hormones triggering the onset of sustained lactation

Who can participate? Pregnant women intending to breastfeed in Oxfordshire area. 

Summary: Hormones such as prolactin and progesterone play a major role in the breastfeeding process and trigger the onset of milk production within the first few days after childbirth. However, the hormone levels required to stimulate milk production are unknown. At LRF OCEHL we are running this vital study to develop normal ranges for milk producing hormones. This study will help us understand why some breastfeeding mothers have delayed milk production or produce limited quantities of milk. View the INSIGHT Study leaflet.

Visit the study webpage to find out more 

 

 

Giant Panda

Giant PANDA - Pregnancy ANtihypertensive Drugs: which Agent is best?

Who can participate? Pregnant women between 11+0 – 34+6 weeks, over 18 years old with a diagnosis of pregnancy hypertension (Chronic/gestational or Pre-eclampsia).Clinicians’ decision to initiate antihypertensive drugs. Women who have a contraindication to either Labetalol or Nifedipine and are already taking both medications are excluded from participating in this study. 

Summary: The aim of this study is to evaluate the effect of different antihypertensive drugs in women with pregnancy hypertension on maternal and fetal/neonatal outcomes. The primary objective is to evaluate if treatment with nifedipine (calcium channel blocker), compared to labetalol (mixed alpha/beta blocker) in women with pregnancy hypertension, reduces severe maternal hypertension without increasing fetal or neonate adverse events.

Find out more

 

 

 

Open now! The RETHINK Study is a study that aims to see if we can detect those women who may find extra support for early labour useful, to help reduce their chance of a difficult labour and unnecessary intervention.

 

The RETHINK Study aims to see if we can detect those women who may find extra support for early labour useful, to help reduce their chance of a difficult labour and unnecessary intervention. To date research has not shown the best way to support women who are in early labour at home.

Who can participate? This study is open to 18 to 40 year old women who are expecting their first baby, and are planning a hospital birth and who are expecting an uncomplicated pregnancy. 

Summary: This study will follow participants through pregnancy, labour and birth, and into the postnatal period to see if we can identify those women who might benefit from additional support in early labour. To help us do this we would like you to complete two questionnaires, one whilst you are pregnant and the other one around 3 weeks after you have had your baby, or 3 weeks from your expected due date if you give birth to your baby earlier than anticipated. We will also be asking for your permission for your hospital to tell us some details about your labour and birth.

Find out more

 

Pfizer Clinical Trial

The Pfizer Maternal C-19 Vaccine Trial at Oxford University Hospitals NHS Foundation Trust for women between 24-34 weeks pregnant.

The Nuffield Department of Women’s and Reproductive Health’s team of doctors, research midwives and nurses are delivering this critical trial to evaluate the safety, tolerability, and immunogenicity of the Pfizer vaccine in pregnant women.

Please find the flyer with more information here

For more information please email: osprea@wrh.ox.ac.uk or call 01865 221107

 

 

 

INGR1D Study in the Thames Valley

INGR1D A large screening study in the Thames Valley to identify infants who are at risk of developing type 1 diabetes.

Who can participate? Any pregnant woman in the Thames Valley can participate.

Summary: In the first week of life, newborns are checked for treatable metabolic and hormonal disorders as part of the standard newborn screening tests. We would like to let you know about the option of another free screening test to identify children at high risk of developing type 1 diabetes. The test is available as part of a research study being carried out by staff of the NHS and the University of Oxford. This extra test can be performed on blood that has already been collected. There are no extra needles or blood tests required for this diabetes screening and taking part is voluntary. 

Read more

 

The National Registry of Rare Kidney Diseases (RaDaR) is a research initiative by UK kidney specialist (the Renal Association and the UK Renal Registry). It is designed to gather information from patients with rare kidney disease and in particular women with chronic kidney disease (CKD). The group aims to look into how women with CKD cope with pregnancy and what can be done to improve care.

RaDaR - Kidney disease and pregnancy. 

Who can participate? Women with chronic kidney disease who have, or have had, a pregnancy.

Summary: The National Registry of Rare Kidney Diseases (RaDaR) is a research initiative by UK kidney specialist (the Renal Association and the UK Renal Registry). It is designed to gather information from patients with rare kidney disease and in particular women with chronic kidney disease (CKD). The group aims to look into how women with CKD cope with pregnancy and what can be done to improve care. Read more

Pre-eclampsia Study - Study of placental particle shedding and the maternal inflammatory response in pre-eclampsia

Who can participate? Women with pre-eclampsia and women without pre-eclampsia.

Summary: The Purpose of the study is to find out more about what causes and how to predict pre-eclampsia. We need to compare the results of certain tests on blood and placental samples from pregnant women with pre-eclampsia with those of women without pre-eclampsia. Read more

BIRTH STUDIES 

INGR1D Study in the Thames Valley

INGR1D A large screening study in the Thames Valley to identify infants who are at risk of developing type 1 diabetes.

Who can participate? Any pregnant woman in the Thames Valley can participate.

Summary: In the first week of life, newborns are checked for treatable metabolic and hormonal disorders as part of the standard newborn screening tests. We would like to let you know about the option of another free screening test to identify children at high risk of developing type 1 diabetes. The test is available as part of a research study being carried out by staff of the NHS and the University of Oxford. This extra test can be performed on blood that has already been collected. There are no extra needles or blood tests required for this diabetes screening and taking part is voluntary. 

Read more

POST NATAL STUDIES 

Cleft Collective

Cleft Study The Cleft Collective Cohort Studies

Who can participate? Women who have received a diagnosis of cleft palate/lip during their pregnancy.

Summary: The Cleft Collective is the world’s largest cleft lip and palate research programme. We are developing two cohort studies. We will follow each family as their child grows up and keep in touch along the way. Read more